Long-term real-world data of ustekinumab in ulcerative colitis: the Stockholm Ustekinumab Study (STOCUSTE)
In this group of patients with difficult-to-treat ulcerative colitis, UST was shown to be effective in the majority, with high drug persistence at 12 months in combination with a favorable safety profile.
Authors
- Christina Wennerström (ORCID: https://orcid.org/0000-0002-0111-3416)
- Charlotte Höög
- Mikael Lördal
- Francesca Bello
- Sven Almér (ORCID: https://orcid.org/0000-0001-9334-1821)
- Ole Forsberg
- Haider Sabhan
- Charlotte Söderman
- Fredrik Johansson (ORCID: https://orcid.org/0000-0001-7345-2313)
- Samer Muhsen
- A Borin
Institutions
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Stockholm South General Hospital (SE)
- Saint Göran Hospital (SE)
- Glanrhyd Hospital (GB)
- Janssen (Switzerland) (CH)
Publication Details
- Journal
- European Journal of Gastroenterology & Hepatology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1097/meg.0000000000002854
- Citations
- 4
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 2.20
Funders
- Cilag